Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

Leuk Lymphoma. 2012 Oct;53(10):2051-3. doi: 10.3109/10428194.2012.666543. Epub 2012 Apr 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Brentuximab Vedotin
  • Female
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / genetics
  • Hodgkin Disease / metabolism*
  • Humans
  • Immunoconjugates / therapeutic use*
  • Ki-1 Antigen / genetics
  • Ki-1 Antigen / metabolism*
  • Male
  • Treatment Failure
  • Young Adult

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin